Latest research and treatment of advanced-stage epithelial ovarian cancer
作者： Robert L. Coleman , Bradley J. Monk , Anil K. Sood , Thomas J. Herzog
关键词:
摘要: … burden and stagnant mortality statistics, despite prolific drug development. Robust clinical … with lagging clinical investigation and limited patient resources. Nevertheless, growth in our …
utsystem.edu
nature.com参考文章(113)
Franco M Muggia, Maria José Echarri Gonzalez, Robin Green, Intraperitoneal Drug Delivery for Ovarian Cancer: Why, How, Who, What, and When? Oncology. ,vol. 25, pp. 156- 170 ,(2011)
Songjian Lu, Xinghua Lu, Integrating genome and functional genomics data to reveal perturbed signaling pathways in ovarian cancers. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. ,vol. 2012, pp. 72- 78 ,(2012)
Griffiths Ct, Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute monograph. ,vol. 42, pp. 101- 104 ,(1975)
Jo Morrison, Krishnayan Haldar, Sean Kehoe, Theresa A Lawrie, None, Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Cochrane Database of Systematic Reviews. ,vol. 2019, ,(2012) , 10.1002/14651858.CD005343.PUB3
P G Rose, J A Blessing, A R Mayer, H D Homesley, Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology. ,vol. 16, pp. 405- 410 ,(1998) , 10.1200/JCO.1998.16.2.405
Hui Chen, Fang Fang, Guan J Liu, Huan Yu Xie, Juan Zou, Dan Feng, Maintenance chemotherapy for ovarian cancer Cochrane Database of Systematic Reviews. ,vol. 2013, ,(2013) , 10.1002/14651858.CD007414.PUB3
W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, I Hudson, C Broom, C Scarabelli, N Davidson, M Spanczynski, G Bolis, H Malmström, R Coleman, S C Fields, J F Heron, Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 15, pp. 2183- 2193 ,(1997) , 10.1200/JCO.1997.15.6.2183
Martine J. Piccart, John A. Green, Angel Jimenez Lacave, Nick Reed, Ignace Vergote, Pierluigi Benedetti-Panici, Andrea Bonetti, Vera Kristeller-Tome, Cesar Mendiola Fernandez, Desmond Curran, Martine Van Glabbeke, Denis Lacombe, Marie-Claire Pinel, Serge Pecorelli, Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group Journal of Clinical Oncology. ,vol. 18, pp. 1193- 1202 ,(2000) , 10.1200/JCO.2000.18.6.1193
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, Philipp Harter, Isabelle Ray-Coquard, Jacobus Pfisterer, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. ,vol. 115, pp. 1234- 1244 ,(2009) , 10.1002/CNCR.24149
Nicole D. Fleming, Ilana Cass, Christine S. Walsh, Beth Y. Karlan, Andrew J. Li, CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer Gynecologic Oncology. ,vol. 121, pp. 249- 252 ,(2011) , 10.1016/J.YGYNO.2011.01.014